Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 201

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab

Open access
Brunner, Patrick M., Pavel, Ana B., Khattri, Saakshi, Leonard, Alexandra, Malik, Kunal, Rose, Sharon, Jim On, Shelbi, Vekaria, Anjali S., Traidl-Hoffmann, Claudia, Singer, Giselle K., Baum, Danielle, Gilleaudeau, Patricia, Sullivan-Whalen, Mary, Fuentes-Duculan, Judilyn, Li, Xuan, Zheng, Xiuzhong, Estrada, Yeriel, Garcet, Sandra, Wen, Huei-Chi, Gonzalez, Juana, Coats, Israel, Cueto, Inna, Neumann, Avidan U., Lebwohl, Mark G., Krueger, James G., Guttman-Yassky, Emma · 2019 · Journal of Allergy and Clinical Immunology

Abstract

Background: IL‐22 is potentially a pathogenic cytokine in patients with atopic dermatitis (AD), but the molecular effects of IL‐22 antagonism have not been defined in human subjects. Objective: We sought to evaluate the cellular and molecular effects of IL‐22 blockade in tissues from patients with moderate‐to‐severe AD. Methods: We assessed lesional and nonlesional skin from 59 patients with moderate‐to‐severe AD treated with anti–IL‐22 (fezakinumab) versus placebo (2:1) using transcriptomic and immunohistochemistry analyses. Results: Greater reversal of the AD genomic profile was seen with fezakinumab versus placebo, namely 25.3% versus 10.5% at 4 weeks (P = 1.7 × 10−5) and 65.5% versus 13.9% at 12 weeks (P = 9.5 × 10−19), respectively. Because IL‐22 blockade showed clinical efficacy only in patients with severe AD, we used baseline median IL‐22 mRNA expression to stratify for high (n = 30) and low (n = 29) IL‐22 expression groups. Much stronger mean transcriptomic improvements were seen with fezakinumab in the IL‐22–high drug‐treated group (82.8% and 139.4% at 4 and 12 weeks, respectively) than in the respective IL‐22–high placebo‐treated group (39.6% and 56.3% at 4 and 12 weeks) or the IL‐22–low groups. Significant downregulations of multiple immune pathways, including TH1/CXCL9, TH2/CCL18/CCL22, TH17/CCL20/DEFB4A, and TH22/IL22/S100A's, were restricted to the IL‐22–high drug group (P < .05). Consistently, tissue predictors of clinical response were mostly genes involved in T‐cell and dendritic cell activation and differentiation. Conclusions: This is the first report showing a profound effect of IL‐22 blockade on multiple inflammatory pathways in AD. These data, supported by robust effects in patients with high IL‐22 baseline expression, suggest a central role for IL‐22 in AD, indicating the need for a precision medicine approach for improving therapeutic outcomes in patients with AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2018.07.028

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 201

Metadata

Authors
Brunner, P. M., Pavel, A. B., Khattri, S., Leonard, A., Malik, K., Rose, S., Jim On, S., Vekaria, A. S., Traidl-Hoffmann, C., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., Fuentes-Duculan, J., Li, X., Zheng, X., Estrada, Y., Garcet, S., Wen, H.-C., Gonzalez, J., Coats, I., Cueto, I., Neumann, A. U., Lebwohl, M. G., Krueger, J. G., & Guttman-Yassky, E.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2019-01
Volume
143
Issue
1
Pages
142-154
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2887882336
Cited by
201
References
13
FWCI
19.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.